Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what the reasons are for the higher level of NICE Health Technology Assessments of new blood cancer treatments that have been terminated compared to Health Technology Assessments for other forms of cancer treatment.

In the last 10 years, where the National Institute for Health and Care Excellence (NICE) has been able to make a recommendation, 92% of blood cancer treatment recommendations were positive. This is significantly higher than the overall rate for cancer treatments (80%).

NICE has made 97 positive recommendations for blood cancer treatments over the last decade, five times more than in the previous ten years. NICE can only recommend treatments when the evidence shows that they provide benefits for patients and value for money to the taxpayer.

NICE cannot evaluate treatments without information from the companies. If a company withdraws from the evaluation process, the assessment is terminated. For blood cancers, the majority of terminated appraisals were because the company did not provide an evidence submission or the technology was unlikely to be a cost-effective use of National Health Service resources.